kabutan

MediciNova,Inc.(4875) Summary

4875
TSE Standard
MediciNova,Inc.
276
JPY
-3
(-1.08%)
Jan 29, 3:30 pm JST
1.80
USD
Jan 29, 1:30 am EST
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
Yield
ー%
Margin Trading Ratio
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
272 JPY 1.77 USD
Previous Close Jan 28
279 JPY 1.82 USD
High Jan 29, 2:31 pm
279 JPY 1.82 USD
Low Jan 29, 9:14 am
268 JPY 1.74 USD
Volume
92,700
Trading Value
0.03B JPY 0.16M USD
VWAP
271.93 JPY 1.78 USD
Minimum Trading Value
27,600 JPY 180 USD
Market Cap
0.01T JPY 0.09B USD
Number of Trades
165
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Mid
1-Year Average
196
1-Year High Nov 5, 2025
3,850
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 0 58,200
Jan 16, 2026 0 52,500
Jan 9, 2026 0 58,500
Dec 26, 2025 0 58,600
Dec 19, 2025 0 52,600
Company Profile
MediciNova, Inc. is a US-based pharmaceutical development venture focusing on treatments for conditions such as acute asthma attacks.
Sector
Pharmaceuticals
MediciNova, Inc. is a pharmaceutical development company headquartered in the United States, specializing in the development of novel therapeutics for serious diseases. Its lead development product, MN-166 (ibudilast), is being developed for indications including ALS, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence, alcohol use disorder, and Long-COVID. MN-001 (tipelukast) is being developed for non-alcoholic fatty liver disease and idiopathic pulmonary fibrosis. Additionally, a treatment for phenylketonuria is included in the development pipeline. The company has received Fast Track and Orphan Drug designations from the US FDA for several of its development products, indicating a promising development pipeline.